Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, GLP-1RA, Other, Topics

Pfizer Acquires Metsera in $7.3B deal; Clive Meanwell Strikes Gold…Again 

Here is a brief preview of this blast: Pfizer announced it entered into a definitive agreement to acquire Metsera, providing the company access to Metsera’s obesity portfolio, including MET-097i (QW/QM SC GLP-1RA), MET-233i (QM SC amylin analog), MET-224o (oral GLP-1RA), and MET-097o (oral GLP-1RA). An associated call was held (view slides). The deal comes following a series of setbacks to Pfizer’s own obesity development program, including the danuglipron discontinuation earlier this year (previous FENIX insight). Below, FENIX provides an overview of the acquisition, commentary from Pfizer, and insight into how this move transforms the future obesity landscape.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.